Your browser doesn't support javascript.

Biblioteca Virtual em Saúde


Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®.

Valis, Martin; Sarláková, Jana; Halúsková, Simona; Klímová, Blanka; Potuzník, Pavel; Peterka, Marek; Kuca, Kamil; Stourac, Pavel; Mares, Jan; Pavelek, Zbysek.
Expert Opin Drug Deliv; 17(5): 719-724, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-32315204


Adherence to Multiple Sclerosis (MS) treatment is considered one of the crucial factors for ensuring optimal clinical outcomes. Research has shown that the use of self-injector devices improves patient compliance with treatment. Therefore, the main purpose of this study is to evaluate the ease of use of RebiSmart® 2.0 in clinically isolated syndrome/relapsing-remitting MS patients during 12 months treatment period.


A total number of 290 subjects entered into data collection; 249 (86%) of them completed the whole 12 months study period. The primary endpoints and the secondary endpoints were assessed by the User Study Questionnaire. Adherence data were retrieved from RebiSmart® 2.0 (Menu - Dose History) on the respective patient's visit. Outcome measures also included Expanded Disability Status Score, Kurtzke Functional Systems, and Modified Social Support Survey, Modified Social Support Survey-5.


This study demonstrated a very high proportion (>95%) of patients with a positive rating of the overall ease of use and the overall convenience of RebiSmart®. The proportion of patients with a positive rating of the ease of use by individual domains and the functions of RebiSmart® were also high (>80%).


The findings demonstrate a very good perception of the usability of the device by patients overall and in its individual functions.
Selo DaSilva